These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28128096)

  • 1. Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate.
    Horcajada JP; Sorlí L; Luque S; Benito N; Segura C; Campillo N; Montero M; Esteve E; Mirelis B; Pomar V; Cuquet J; Martí C; Garro P; Grau S
    Int J Antimicrob Agents; 2016 Dec; 48(6):725-727. PubMed ID: 28128096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria.
    Zaidi ST; Al Omran S; Al Aithan AS; Al Sultan M
    J Clin Pharm Ther; 2014 Jun; 39(3):272-6. PubMed ID: 24593154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia.
    Omrani AS; Alfahad WA; Shoukri MM; Baadani AM; Aldalbahi S; Almitwazi AA; Albarrak AM
    Ann Clin Microbiol Antimicrob; 2015 Jan; 14():3. PubMed ID: 25591721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa.
    Sorlí L; Luque S; Segura C; Campillo N; Montero M; Esteve E; Herrera S; Benito N; Alvarez-Lerma F; Grau S; Horcajada JP
    BMC Infect Dis; 2017 Jan; 17(1):11. PubMed ID: 28056821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.
    Cheng CY; Sheng WH; Wang JT; Chen YC; Chang SC
    Int J Antimicrob Agents; 2010 Mar; 35(3):297-300. PubMed ID: 20045293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
    Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colistin nephrotoxicity in critically ill patients after implementation of a new dosing strategy.
    Ozel AS; Ergönül Ö; Korten V
    J Infect Dev Ctries; 2019 Oct; 13(10):877-885. PubMed ID: 32084017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
    Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium.
    Hassan MM; Gaifer Z; Al-Zakwani IS
    Int J Clin Pharm; 2018 Apr; 40(2):444-449. PubMed ID: 29542034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study.
    Sorlí L; Luque S; Grau S; Berenguer N; Segura C; Montero MM; Alvarez-Lerma F; Knobel H; Benito N; Horcajada JP
    BMC Infect Dis; 2013 Aug; 13():380. PubMed ID: 23957376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system.
    Pogue JM; Lee J; Marchaim D; Yee V; Zhao JJ; Chopra T; Lephart P; Kaye KS
    Clin Infect Dis; 2011 Nov; 53(9):879-84. PubMed ID: 21900484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colistin nephrotoxicity increases with age.
    Balkan II; Dogan M; Durdu B; Batirel A; Hakyemez IN; Cetin B; Karabay O; Gonen I; Ozkan AS; Uzun S; Demirkol ME; Akbas S; Kacmaz AB; Aras S; Mert A; Tabak F
    Scand J Infect Dis; 2014 Oct; 46(10):678-85. PubMed ID: 25073536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study.
    Phe K; Shields RK; Tverdek FP; Aitken SL; Guervil DJ; Lam WM; Musgrove RJ; Luce AM; Tam VH
    J Antimicrob Chemother; 2016 Dec; 71(12):3585-3587. PubMed ID: 27543655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections.
    Falagas ME; Rafailidis PI; Kasiakou SK; Hatzopoulou P; Michalopoulos A
    Clin Microbiol Infect; 2006 Dec; 12(12):1227-30. PubMed ID: 17121631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Renal Toxicity of Colistin Therapy With Neutrophil Gelatinase-associated Lipocalin: a Biomarker of Renal Tubular Damage.
    Ordooei Javan A; Salamzadeh J; Shokouhi S; Sahraei Z
    Iran J Kidney Dis; 2017 Nov; 11(6):447-455. PubMed ID: 29190605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colistin Use in Patients with Chronic Kidney Disease: Are We Underdosing Patients?
    Sorli L; Luque S; Li J; Rodríguez E; Campillo N; Fernandez X; Soldado J; Domingo I; Montero M; Grau S; Horcajada JP
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30717123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Toxicity of High-Dose Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections: A Comparative Study of a Matched Series.
    Trifi A; Abdellatif S; Daly F; Mahjoub K; Nasri R; Oueslati M; Mannai R; Bouzidi M; Ben Lakhal S
    Chemotherapy; 2016; 61(4):190-6. PubMed ID: 26863534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients.
    Falagas ME; Rafailidis PI; Ioannidou E; Alexiou VG; Matthaiou DK; Karageorgopoulos DE; Kapaskelis A; Nikita D; Michalopoulos A
    Int J Antimicrob Agents; 2010 Feb; 35(2):194-9. PubMed ID: 20006471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of colistin methanesulfonate sodium in correlation with pharmacokinetic parameters in critically ill patients with multi-drug resistant bacteria-mediated infection: A systematic review and meta-analysis.
    Son JY; Kim S; Porsuk T; Shin S; Choi YJ
    J Infect Public Health; 2024 May; 17(5):843-853. PubMed ID: 38554590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study.
    Moni M; Sudhir AS; Dipu TS; Mohamed Z; Prabhu BP; Edathadathil F; Balachandran S; Singh SK; Prasanna P; Menon VP; Patel T; Patel P; Kaye KS; Menon VP
    Int J Infect Dis; 2020 Nov; 100():497-506. PubMed ID: 32781161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.